Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
After dose 3 of CYD-TDV, antibody titers were comparable for the concomitant and sequential groups across all serotypes, with between-group ratios close to 1 (serotype 1: 0.977; serotype 2: 0.911; serotype 3: 0.921; serotype...
SMS appears to be non-inferior to UCCS in the maintenance of euglycemia, thus emerging as a promising alternative to the treatment of GSD Ia.
Including how the body absorbs the medicine metrics in TGI models should be conducted carefully when no how the body absorbs the medicine samples are available.
Conclusions: In Phase 3 trials, the benefit-risk ratio for lemborexant is favorable as measured by NNT, NNH, and LHH.
Generally, switching from 3-/4-drug tenofovir alafenamide-based regimens to dolutegravir/lamivudine improved metabolic parameters, particularly when switching from boosted regimens.
Dasiglucagon provided rapid and effective reversal of low blood sugar in adults with type 1 diabetes, with safety and tolerability similar to those reported for reconstituted glucagon injection.
We aim to accrue 330 patients from 47 institutions over 5 years.
Compared with minimal metabolic effect of NET, NCT worsens metabolic profiles, which were recovered over 3 years.
IVT-AFL single-drug treatment was efficacious for the treatment of Japanese patients with PCV, and the addition of rescue PDT did not show additional benefits.
Similar to the global study population, upadacitinib demonstrated clinical efficacy superior to placebo in the Japanese subpopulation.
These findings indicate that treatment with enzalutamide plus androgen deprivation therapy provides improvements in men with bone and/or lymph node metastases but may be less effective in men with visceral patterns of spread.
Conclusion : A positive efficacy-TEAE balance exists for patients increasing their lasmiditan dose for treatment of a subsequent migraine attack.
Clinically meaningful and statistically significant improvements in WV, step length, and cadence under all four test conditions were observed in patients with spastic hemiparesis after each aboBoNT-A treatment cycle.
At the time of the interim analysis, response rate findings are comparable to the responses seen in a similar patient population in the phase I/II study.
C minss was the best exposure predictor for the JIA-ACR response: log odds for response increased in proportion to log-transformed C minss ; JIA-ACR30 approached a plateau when C minss ≥ 10 μg/mL.
WHAT QUESTION DID THIS STUDY ADDRESS?
There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain.
Henagliflozin 5 mg and 10 mg as single-drug treatment provided effective glycaemic control, reduced body weight and blood pressure, and was generally well tolerated.
The combination of TIL +DC showed no difference in the persistence of MART-1 TIL compared with TIL therapy alone.
Central monitoring utilized primary study data in a five-tiered approach, including (1) real-time data checks & topic-specific intervention reports, (2) missing forms reports, (3) quality assurance metrics, (4) critical data...
Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated.
Immune biomarkers were not predictive of added benefit of gemcitabine in a cohort of mixed breast cancer subtypes.
KPI-121 ophthalmic suspension 0.25% seemed to be safe and well tolerated when dosed QID for 2 to 4 weeks in those DED subjects included in the 4 trials.
By hastening reepithelialization, improving burn-related pain, and decreasing treatment-related costs, Nile tilapia fish skin could benefit the resource-poor public health systems of developing.
The primary endpoint is overall survival.
MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit.
Women's attitudes toward contraceptives can impact their willingness to concurrently use and adhere to a novel HIV prevention product.
The PFS benefit appears clinically significant over fulvestrant alone, with a 7.9 months, non-significant, improvement in overall survival.
Neurocognitive disturbances, measured with the MMSE at baseline, are an unfavorable prognostic factor for both PFS and OS in adult PCNSL patients up to 70 years-old.
Adjusting for E2 dose and baseline E2 level, on-trial E2 levels were significantly associated with time since menopause, current smoking, and current alcohol use.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
